SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN),
developer of advanced diagnostic products, announced today it has expanded its
molecular reagent product portfolio to include two new products to detect
sequences for respiratory viral pathogens: a multiplex solid-phase
hybridization set of reagents that can be employed to develop and validate
assays for the detection of the sequences of six human respiratory viruses
prevalent during flu season, and a research-use-only (RUO) real-time PCR probe
and primer set for the identification of the influenza A and B viruses.
The NGEN(TM) RVA analyte specific reagent (ASR) product can be used to
develop and validate assays to detect the sequences of and differentiates
among influenza A and B, respiratory syncytial virus and parainfluenza 1, 2
and 3. Assays validated using NGEN(TM) RVA ASR can be carried out with
various sample types, including nasal swabs and, once validated by the
laboratory, can be used as a clinical diagnostic test. The product was
developed in cooperation with Prodesse, Inc., a leading supplier of
molecular-based reagents for infectious disease targets, and is available in
the United States as an ASR for which analytical and performance
characteristics are not established. The product has been CE marked in the
European Union as an in vitro diagnostic and is available outside the United
Additionally, Nanogen has expanded its real-time PCR product group with an
RUO probe and primer set for the identification of the influenza A and B
viruses. The MGB Eclipse(R) Flu A/B RUO product uses the company's
proprietary MGB(TM) technology to provide melt curve analysis that
differentiates the two viral strains for each sample. The new MGB Eclipse(R)
Flu A/B primer and probe set, along with the recently released Enterovirus and
hMPV reagents, complement Nanogen's growing MGB Alert(TM) product family of
ASRs targeting infectious agents, such as herpes viruses and pneumonias.
Both sets and reagents target a nucleic acid sequence also found in the
H5N1 strain of the influenza A virus, also known as avian flu. Laboratories
interested in screening for avian flu can choose between the real-time PCR
research reagents or the set of ASRs that can be validated for clinical use.
Positives could then be sequenced for epidemiological studies.
"The market for respiratory virus testing is estimated to be over
$100 million annually. With the shipment of these new products, Nanogen is
making a strong play to grab a piece of that market," noted Howard C.
Birndorf, chairman and chief executive officer of Nanogen. "Traditionally,
labs testing for flu have been limited to choosing between simple rapid tests,
which often lack sensitivity and specificity, or culture-based tests that are
slow to get results. Our advanced molecular-based technologies offer clinical
and research labs additional options. We believe our products will enable
changes in laboratory procedures that can influence better prescribing
practices and improve patient care."
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict, diagnose, and
ultimately help treat disease. The company's products include real-time PCR
reagents, the NanoChip(R) electronic microarray platform and a line of
reagents useful in rapid diagnostic tests. Nanogen's ten years of pioneering
research involving nanotechnology holds the promise of miniaturization and
continues to be supported for its potential for diagnostic and biowarfare
applications. For additional information please visit Nanogen's website at
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
products under development can be successfully developed and commercialized,
whether patents owned or licensed by Nanogen will be developed into products,
whether the patents owned by Nanogen offer any protection against competitors
with competing technologies, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.